Background: Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a translational model with relevance to many of the symptoms of schizophrenia. Previous studies have focused specifically on the prefrontal cortex (PFC) because this region is implicated in many of the functional deficits associated with this disorder and shows reduced activity (hypofrontality) in schizophrenia patients. Chronic NMDA antagonist treatment in rodents can also induce hypofrontality, although paradoxically acute NMDA receptor antagonist administration induces metabolic hyperfrontality. Methods: In this study, we use 2-deoxyglucose imaging data in mice to characterize acute ketamine-induced alterations in regional funct...
N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizoph...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces e...
Background: Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurg...
The N-methyl-D-aspartic acid (NMDA)-hypofunction theory of schizophrenia suggests that schizophrenia...
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces e...
Invited conference talk http://www1.dgppn-kongress.de/guest/ID74d0835ed00ceb/SciProgramSessionsList?...
Background: Schizophrenia has been associated with disturbances of thalamic functioning. In light o...
Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizoph...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces e...
Background: Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurg...
The N-methyl-D-aspartic acid (NMDA)-hypofunction theory of schizophrenia suggests that schizophrenia...
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces e...
Invited conference talk http://www1.dgppn-kongress.de/guest/ID74d0835ed00ceb/SciProgramSessionsList?...
Background: Schizophrenia has been associated with disturbances of thalamic functioning. In light o...
Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
N-methyl-D-aspartate receptor (NMDAR) hypofunction is a leading pathophysiological model of schizoph...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces e...